Results 61 to 70 of about 720,989 (310)

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma

Journal of Experimental & Clinical Cancer Research
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a poor prognosis. The critical role of epigenetic alterations such as changes in DNA methylation, histones modifications, and chromatin ...
Daniel Oyon, Amaya Lopez-Pascual, Borja Castello-Uribe, Iker Uriarte, Giulia Orsi, Sofia Llorente, Jasmin Elurbide, Elena Adan-Villaescusa, Emiliana Valbuena-Goiricelaya, Ainara Irigaray-Miramon, Maria Ujue Latasa, Luz A. Martinez-Perez, Luca Reggiani Bonetti, Felipe Prosper, Mariano Ponz-Sarvise, Silvestre Vicent, Antonio Pineda-Lucena, David Ruiz-Clavijo, Bruno Sangro, Urko Aguirre Larracoechea, Tian V. Tian, Andrea Casadei-Gardini, Irene Amat, Maria Arechederra, Carmen Berasain, Jesus M. Urman, Matias A. Avila, Maite G. Fernandez-Barrena   +27 more
doaj   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-Lack of association between activating AKT mutation and AKT inhibition-derived efficacy [PDF]

, 2019
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced ...
Boix, Oliver, Hess, Dagmar, Hurvitz, Sara A, Joerger, Markus, Lagkadinou, Eleni, Ma, Cynthia, Moulder, Stacy, Ocker, Matthias, Rentzsch, Christine, Rudolph, Marion, Schneeweiss, Andreas, Thiele, Silke, Tsimberidou, Apostolia M, Varga, Andrea, Wilkinson, Gary   +14 more
core   +3 more sources

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Sweet dreams could be made of this: carbohydrate‐responsive element‐binding protein (ChREBP) as a target for hepatocellular carcinoma therapy

Molecular Oncology
Rewiring of cellular metabolism is now fully recognized as a hallmark of cancer. Tumor cells reprogram metabolic pathways to meet the energetic and macromolecular demands to support unrestricted growth and survival under unfavorable conditions.
Maite G. Fernández‐Barrena, Matías A. Avila   +1 more
doaj   +1 more source

Biological functions of CDK5 and potential CDK5 targeted clinical treatments. [PDF]

, 2017
Cyclin dependent kinases are proline-directed serine/threonine protein kinases that are traditionally activated upon association with a regulatory subunit.
Casimiro, Mathew C., Pestell, Richard G., Shupp, Alison   +2 more
core   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Treatment and Outcomes of Pancreatic Cancer in Armenia: A Retrospective Study From Resource-Limited Settings

JCO Global Oncology
PURPOSEPancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.METHODSThis is a ...
Elen Baloyan, Davit Zohrabyan, Liana Safaryan, Armen Avagyan, Lilit Harutyunyan, Vardan Bardakhchyan, Jemma Arakelyan, Amalya Sargsyan, Martin Harutyunyan, Mariam Mailyan, Gevorg Tamamyan, Samvel Bardakhchyan   +11 more
doaj   +1 more source